Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06143631

Prescription of Letrozole for Uterine Myoma

Letrozole for Treatment of Uterine Fibroids: A Randomized, Placebo-Controlled Trial

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
140 (estimated)
Sponsor
University of California, San Francisco · Academic / Other
Sex
Female
Age
21 Years – 53 Years
Healthy volunteers
Accepted

Summary

The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

Conditions

Interventions

TypeNameDescription
DRUGLetrozole 2.5mgOral letrozole 2.5mg/day
OTHERPlaceboPlacebo capsule

Timeline

Start date
2024-07-24
Primary completion
2027-01-30
Completion
2027-04-30
First posted
2023-11-22
Last updated
2026-02-03

Locations

5 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06143631. Inclusion in this directory is not an endorsement.

Prescription of Letrozole for Uterine Myoma (NCT06143631) · Clinical Trials Directory